Takeda opposes the misuse, abuse, and diversion of prescription medicines approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD medicines have demonstrated effectiveness in managing ADHD symptoms, but, like all prescription medications, they come with potential side effects and should be used only as prescribed and under careful medical supervision. Takeda firmly believes that only trained and licensed healthcare professionals should diagnose and evaluate individuals for ADHD.
As a leader in ADHD education and treatment options, Takeda’s first obligation is to patients who have been appropriately diagnosed with ADHD, a real psychiatric disorder that can be managed under the care and direction of a healthcare professional. We believe that abuse, misuse or diversion of ADHD medicines can negatively impact patients who rely on these medicines by effecting the ability of patients to access their medicine as prescribed.
As a values-based company, Takeda is concerned about reports of misuse, abuse, and diversion of ADHD medicines, and, as such, is committed to combating this nonmedical use.
CPAMM uses its knowledge to provide
information and prevent the nonmedical use
of ADHD medications.